阿仑膦酸钠联合唑来膦酸治疗绝经后骨质疏松症患者的临床效果

目的探讨阿仑膦酸钠联合唑来膦酸治疗绝经后骨质疏松症(PMO)患者的临床效果。方法选取新疆克拉玛依市中心医院2017年9月至2020年1月收治的PMO患者122例作为研究对象,随机分为单一用药组和联合用药组,各61例。单一用药组仅采用阿仑膦酸钠治疗,联合用药组采用阿仑膦酸钠联合唑来膦酸方案,比较两组治疗前后骨密度(BMD)、骨源性碱性磷酸酶(BALP)、骨钙素(BGP)及抗酒石酸酸性磷酸酶-5b(TRACP-5b)及不良反应发生情况。结果治疗后,联合用药组股骨颈、腰椎以及Ward’s三角区的BMD明显高于单一用药组,差异有统计学意义(P<0.05);治疗后,联合用药组BALP、TRACP-5b以及BGP明显低于单一用药组,差异有统计学意义(P<0.05);两组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论阿仑膦酸钠联合唑来膦酸能够提高骨质密度,改善骨质代谢,为临床治疗提供了新的治疗方案。

Clinical Effects of Alendronate Combined with Zoledronic Acid in the Treatment of Patients with Postmenopausal Osteoporosis

Objective To explore the effect of alendronate combined with zoledronic acid in the treatment of patients with postmenopausal osteoporosis. Methods A total of 122 patients with postmenopausal osteoporosis(PMO) admitted to Central Hospital of Karamay City from September 2017 to January 2020 were selected as the research objects and were randomly divided into a single group(n=61) and a combined group(n=61). The single group was treated with alendronate only, while the combined group was treated with alendronate combined with zoledronic acid. Bone mineral density(BMD), bone metabolism indexes bone alkaline phosphatase(BALP), osteocalcin(BGP) and tartrate resistant acid phosphatase-5b(TRACP-5b)] and adverse reactions between the 2 groups before and after treatment were compared. Results After treatment, the BMD of the femoral neck, lumbar spine and Ward’s triangle of the combined medication group was significantly higher than that of the single medication group, and the difference was statistically significant(P<0.05);after treatment, the combined medication group had significantly lower BALP, TRACP-5b and BGP than the single medication group, the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the 2 groups during the treatment period(P>0.05). Conclusion Alendronate combined with zoledronic acid can improve bone density and improve bone metabolism, providing a new therapeutic regimen for clinical treatment.